These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 30519392)

  • 21. MS-275 combined with cisplatin exerts synergistic antitumor effects in human esophageal squamous cell carcinoma cells.
    Liu T; Guan F; Wang Y; Zhang Z; Li Y; Cui Y; Li Z; Liu H; Zhang Y; Wang Y; Ma S
    Toxicol Appl Pharmacol; 2020 May; 395():114971. PubMed ID: 32217144
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EZH2 Contributes To Cisplatin Resistance In Breast Cancer By Epigenetically Suppressing miR-381 Expression.
    Dou D; Ge X; Wang X; Xu X; Zhang Z; Seng J; Cao Z; Gu Y; Han M
    Onco Targets Ther; 2019; 12():9627-9637. PubMed ID: 32009798
    [TBL] [Abstract][Full Text] [Related]  

  • 23. LncRNA SNHG1 promotes tumor progression and cisplatin resistance through epigenetically silencing miR-381 in breast cancer.
    Zhang M; Yang L; Hou L; Tang X
    Bioengineered; 2021 Dec; 12(2):9239-9250. PubMed ID: 34806925
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Down-regulation of CASC2 contributes to cisplatin resistance in gastric cancer by sponging miR-19a.
    Li Y; Lv S; Ning H; Li K; Zhou X; Xv H; Wen H
    Biomed Pharmacother; 2018 Dec; 108():1775-1782. PubMed ID: 30372881
    [TBL] [Abstract][Full Text] [Related]  

  • 25. miR-381 overcomes cisplatin resistance in breast cancer by targeting MDR1.
    Yi D; Xu L; Wang R; Lu X; Sang J
    Cell Biol Int; 2019 Jan; 43(1):12-21. PubMed ID: 30444043
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Knockdown of long non-coding RNA HOTAIR reverses cisplatin resistance of ovarian cancer cells through inhibiting miR-138-5p-regulated EZH2 and SIRT1.
    Zhang Y; Ai H; Fan X; Chen S; Wang Y; Liu L
    Biol Res; 2020 Apr; 53(1):18. PubMed ID: 32349783
    [TBL] [Abstract][Full Text] [Related]  

  • 27. miR-145 sensitizes esophageal squamous cell carcinoma to cisplatin through directly inhibiting PI3K/AKT signaling pathway.
    Zheng TL; Li DP; He ZF; Zhao S
    Cancer Cell Int; 2019; 19():250. PubMed ID: 31582906
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circ_0030998 Restrains Cisplatin Resistance Through Mediating miR-1323/PDCD4 Axis in Non-small Cell Lung Cancer.
    Zhu C; Jiang X; Xiao H; Guan J
    Biochem Genet; 2022 Dec; 60(6):2434-2454. PubMed ID: 35460386
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insulin-like growth factor 2 mRNA-binding protein 2-stabilized long non-coding RNA Taurine up-regulated gene 1 (TUG1) promotes cisplatin-resistance of colorectal cancer via modulating autophagy.
    Xia C; Li Q; Cheng X; Wu T; Gao P; Gu Y
    Bioengineered; 2022 Feb; 13(2):2450-2469. PubMed ID: 35014946
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CCT4 knockdown enhances the sensitivity of cisplatin by inhibiting glycolysis in human esophageal squamous cell carcinomas.
    Fang J; Ma Y; Li Y; Li J; Zhang X; Han X; Ma S; Guan F
    Mol Carcinog; 2022 Nov; 61(11):1043-1055. PubMed ID: 36102200
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long non-coding RNA TUG1 is up-regulated in hepatocellular carcinoma and promotes cell growth and apoptosis by epigenetically silencing of KLF2.
    Huang MD; Chen WM; Qi FZ; Sun M; Xu TP; Ma P; Shu YQ
    Mol Cancer; 2015 Sep; 14():165. PubMed ID: 26336870
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Downregulation of ALDH5A1 suppresses cisplatin resistance in esophageal squamous cell carcinoma by regulating ferroptosis signaling pathways.
    Song K; Ma C; Maswikiti EP; Gu B; Wang B; Wang N; Jiang P; Chen H
    Mol Carcinog; 2024 Oct; 63(10):1892-1906. PubMed ID: 38923019
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TUG1 promotes osteosarcoma tumorigenesis by upregulating EZH2 expression via miR-144-3p.
    Cao J; Han X; Qi X; Jin X; Li X
    Int J Oncol; 2017 Oct; 51(4):1115-1123. PubMed ID: 28902349
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PCAT-1 contributes to cisplatin resistance in gastric cancer through miR-128/ZEB1 axis.
    Guo Y; Yue P; Wang Y; Chen G; Li Y
    Biomed Pharmacother; 2019 Oct; 118():109255. PubMed ID: 31352238
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Long non-coding RNA XIST modulates cisplatin resistance by altering PDCD4 and Fas-Lexpressions in human nasopharyngeal carcinoma HNE1 cells
    Wang H; Li W; Tan G
    Nan Fang Yi Ke Da Xue Xue Bao; 2019 Mar; 39(3):357-363. PubMed ID: 31068307
    [TBL] [Abstract][Full Text] [Related]  

  • 36. LINC00261 Suppresses Cisplatin Resistance of Esophageal Squamous Cell Carcinoma Through miR-545-3p/MT1M Axis.
    Wang L; Wang X; Yan P; Liu Y; Jiang X
    Front Cell Dev Biol; 2021; 9():687788. PubMed ID: 34336838
    [TBL] [Abstract][Full Text] [Related]  

  • 37. P53-regulated long non-coding RNA TUG1 affects cell proliferation in human non-small cell lung cancer, partly through epigenetically regulating HOXB7 expression.
    Zhang EB; Yin DD; Sun M; Kong R; Liu XH; You LH; Han L; Xia R; Wang KM; Yang JS; De W; Shu YQ; Wang ZX
    Cell Death Dis; 2014 May; 5(5):e1243. PubMed ID: 24853421
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interference with endogenous EZH2 reverses the chemotherapy drug resistance in cervical cancer cells partly by up-regulating Dicer expression.
    Cai L; Wang Z; Liu D
    Tumour Biol; 2016 May; 37(5):6359-69. PubMed ID: 26631032
    [TBL] [Abstract][Full Text] [Related]  

  • 39. LncRNA DUXAP10 modulates cell proliferation in esophageal squamous cell carcinoma through epigenetically silencing p21.
    Wang Z; Ren B; Huang J; Yin R; Jiang F; Zhang Q
    Cancer Biol Ther; 2018; 19(11):998-1005. PubMed ID: 30215547
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MicroRNA-98 and microRNA-214 post-transcriptionally regulate enhancer of zeste homolog 2 and inhibit migration and invasion in human esophageal squamous cell carcinoma.
    Huang SD; Yuan Y; Zhuang CW; Li BL; Gong DJ; Wang SG; Zeng ZY; Cheng HZ
    Mol Cancer; 2012 Aug; 11():51. PubMed ID: 22867052
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.